Merck's Keytruda Plus Chemotherapy Reduces Risk Of Death By One-Third In Metastatic Cervical Cancer
18/9 17:26
(RTTNews) - Merck & Co., Inc. (MRK) said it presented the full results from the pivotal Phase 3 KEYNOTE-826 trial at the European Society for Medical Oncology Congress 2021. The trial investigated the company's anti-PD-1 therapy KEYTRUDA in combination with chemotherapy with or w...